Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 513

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 513
---
 ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Prophase April 2024 Loan         | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​                 | ​ |    250 | ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Prophase May 2024 Loans          | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​                 | ​ |    790 | ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Prophase July 2024 Loans         | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​                 | ​ |     83 | ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Prophase August 2024 Loans       | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​                 | ​ |     50 | ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Hana Loans                       | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​                 | ​ |    850 | ​ | ​ | ​ | ​                | ​ |      — | ​ | ​ |
| Short-term debt, related parties | ​ | ​ | ​                                     | ​ | ​ | ​                 | $ | 19,273 | ​ | ​ | ​ | ​                | $ | 16,050 | ​ | ​ |

F-66

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO CONDENSED FINANCIAL STATEMENTS

#### SEPTEMBER 30, 2024
<div align='center'>**(Unaudited)**</div>

As of September 30, 2024 and December 31, 2023, the Company’s outstanding debt agreements are all classified as current as all are past due with the exception of the Ewon December 2023 Loan, Prophase August 2024 Loans and approximately $0.6 million of the Hana Loans, which are due within one year. All of the loans are with related parties (see Note 4).

As the Company’s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment of the past due loans until the completion of the Company’s